Home

Federal Government Relations

BioBytes: What are biosimilars?

Biosimilars, also known as follow-on biologics, may eventually expand access and provide patients a more affordable alternative to innovative, lifesaving medicines. 

2010 BIO Legislative Day Fly-In

 The 2010 BIO Legislative Day Fly-In will take place on April 13-14, 2010. Our annual fly-in events provide the opportunity for the BIO members to meet with Congress and to advocate BIO’s legislative agenda. Biotech executives from across the nation are welcomed and encouraged to participate.

Get the Scoop on the Presenting Companies for 8th Annual BIO Investor Forum
Clearing Another Hurdle on the Pathway to Biosimilars
Patient groups join call for data protection
Victory on Biosimilars in Senate HELP Committee - But Still a Long Way from the Finish Line
Tricia Brooks and James Trussell Discuss Stem Cell Research and Parkinson's Cures

BIO supports all avenues of research to investigate therapies for debilitating diseases such as Parkinson's.

The Importance of President Obama's Executive Order on Embryonic Stem Cells

In this interview, BIO President and CEO Jim Greenwood explains the promise of stem cell research and why it is an important first step in bringing new therapies to patients.

The Importance of President Obama’s Executive Order on Embryonic Stem Cells
BIO CEO & Investor Conference: The New Administration & Congress: Short or Loose Change?
BIO leaders Joshua Boger and Jim Greenwood discuss challenges and opportunities for the biotech industry in the Obama Administration and the new Congress
BIO's Joshua Boger and Jim Greenwood Media Briefing
The Smell of Politics is in the Air: Biotech and Political Conventions
Guide to Biotechnology 2008

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

2007-2008 BIO Milestones

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

Letters, Testimony & Comments

Pandemic and All-Hazards Preparedness Reauthorization Act
December 18 2012
Dear Speaker Boehner and Minority Leader Pelosi: On behalf of the Biotechnology Industry Organization (BIO), I am writing with our...
The Renewable Fuels Standard: A Successful Federal Policy that Must Be Defended
October 17 2012
A keynote Address by James C. Greenwood, President & CEO of BIO, to RETECH 2012 in Washington, DC on October 18, 2012. When Admiral...
IP Attache Program: BIO's Congressional Hearing Comments
June 27 2012
  The U.S. Intellectual Property Rights Attaché Program has had significant success and holds immense promise in helping to...
Oppose Costly & Confusing Labeling Amendment to the Agriculture Reform, Food and Jobs Act of 2012
June 21 2012
Senators Sanders and Boxer have introduced an amendment that will result in costly and extreme food labeling requirements. Senate...
The Farm Bill: BIO Opposes the Sanders-Boxer Amendment
June 21 2012
The Biotechnology Industry Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state...
More Letters, Testimony & Comments →

Press Releases

BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
BIO Praises Introduction of the High Technology Small Business Research Incentives Act
September 25 2012
Washington, D.C. (September 25, 2012) – The Biotechnology Industry Organization (BIO) applauds Sens. Robert...
BIO Submits Comments on FDA Draft Guidances on Biosimilars
April 17 2012
Washington, D.C. (April 17, 2012) – The Biotechnology Industry Organization (BIO) submitted comments yesterday...
BIO Applauds Congress for Passage of the Jumpstart Our Business Startups (JOBS) Act
March 27 2012
The Biotechnology Industry Organization (BIO) praises the House and Senate for passage of H.R. 3606, the Jumpstart...
Biotech Leader Provides Testimony at Congressional Hearing on ‘Spurring Job Growth through Capital Formation While Protecting Investors’
March 6 2012
Today, the Senate Committee on Banking, Housing, and Urban Affairs held a hearing on “Spurring Job Growth...
More Press Releases →